Large-scale synthesis of GMP grade N′-[2-(2-thiophene)ethyl]- N′-[2-(5-bromopyridyl)]-thiourea (HI-443), a new anti-HIV drug candidate

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 6, 2007, Pages 330-338

  DuMez, Darin ^a   Venkatachalam, Taracad K ^a   Uckun, Fatih M ^a  

^a Paradigm Pharmaceuticals   (United States)

Author keywords

Anti HIV agents; CAS 258340 15 7; HI 443; Non nucleoside analog reverse transcriptase inhibitors; N 2 (2 thiophene)ethyl N 2 (5 bromopyridyl) thiourea

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HI 443; N' [2 (2 THIOPHENE)ETHYL] N' [2 (5 BROMOPYRIDYL)]THIOUREA; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG IDENTIFICATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG POTENCY; DRUG PURITY; DRUG STRUCTURE; DRUG SYNTHESIS; GOOD MANUFACTURING PRACTICE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

EID: 34447308525     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296627     Document Type: Article

References (20)

1. Balzarini J, Egberink H, Hartmann K, Cahard D, Vahlenkamp T, Thormar H, et al. Antiretrovirus specificity and intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine (stavudine) and its 5′-monophosphate triester prodrug So324. Mol Pharmacol. 1996;50(5):1207-1213.
2. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824-831.
3. Rey D, Schmitt MP, Partisani M, Hess-Kempf G, Krantz V, de Mautort E, et al. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J Acquir Immune Defic Syndr. 2001;27(5):459-462.
4. Richman DD. HIV chemotherapy. Nature. 2001;410(6831): 995-1001.
5. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999;341(25):1874-1881.
6. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001;345(6):398-407.
7. Garcia-Lerma JG, Heneine W. Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing. J Clin Virol. 2001;21(3):197-212.
8. O'Brien WA. Resistance against reverse transcriptase inhibitors. Clin Infect Dis. 2000;30 Suppl 2:S185-192.
9. Pillay D, Taylor S, Richman DD. Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol. 2000;10(4):231-253.
10. Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, et al. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors. Eur J Clin Microbiol Infect Dis. 1999; 18(4):274-282.
11. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998;38(3):153-179.
12. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem Pharmacol. 2000;60(9):1251-1265.
13. Mao C, Vig R, Venkatachalam TK, Sudbeck EA, Uckun FM. Structure-based design of N-[2-(1-piperidinylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 1998;8(16):2213-2218.
14. Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Mao C, et al. N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett 1999;9(24):3411-6.
15. Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM. Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett 2001;11(4):523-8.
16. Uckun FM, Venkatachalam TK, Uckun FM, Venkatachalam TKUckun FM, Venkatachalam TKs; Thiophene-ethyl thiourea compounds and use. US patent 6,124,324. Issued: 9/26/2000.
17. Uckun FM, Qazi S, Venkatachalam TK. N′-[2-(2-Thiophene)ethyl]- N′-[2-(5-bromopyridyl)] thiourea (HI-443), a rationally designed non-nucleoside reverse transcriptase inhibitor compound with potent anti-HIV activity. Arzneimittel-Forschung (Drug Research). 2007;57(5):278-285.
18. Uckun FM, Venkatachalam TK, Erbeck D. In vivo pharmacokinetics, metabolism, toxicty, and anti-HIV activity of N′-[2-(2-thiophene)ethyl]- N′-[2-(5-bromopyridyl)]thiourea (HI-443), a potent non-nucleoside inibitor of HIV reverse transcriptase. Arzneimittel-Forschung (Drug Research). In press 2007.
19. D'Cruz OJ, Uckun FM. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. Curr HIV Res. 2006;4(3):329-345.
20. Uckun FM, Tibbles H, Erbeck D, Venkatachalam TK, Qazi S. In vivo pharmacokinetics and toxicity of a novel hydrophilic oral formulation of the potent non-nucleoside reverse transcriptase inhibitor compound N′-[2-(2-thiophene) ethyl]-N′-[2-(5-bromopyridyl)]-thiourea (HI-443). Arzneimittel-Forschung (Drug Research). 2007;57(4):218-226.